Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2024-04-09 AGM Information
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox : Assemblée Générale Ordinaire et Extraordinaire 2024
AGM Information Classification · 1% confidence The document is a press release ('Communiqué de presse') announcing the postponement and rescheduling of the Annual General Meeting (Assemblée Générale Ordinaire et Extraordinaire) from April 10, 2024, to May 6, 2024. It details the new date, location, and voting procedures. This content directly relates to the formal meeting of shareholders, which falls under the scope of AGM materials. Since it is an announcement about the meeting logistics and not the voting results (DVA) or the proxy materials themselves (PSI), the most appropriate classification is AGM Information (AGM-R). The document length is moderate (5190 chars), but its primary function is to communicate the AGM details.
2024-04-09 French
Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
AGM Information Classification · 1% confidence The document is explicitly titled "Press Release" and concerns the rescheduling of the "Ordinary and Extraordinary Shareholder Meeting" from April 10, 2024, to May 6, 2024, due to a failure to meet the quorum. This document is an announcement regarding the logistics and rescheduling of a shareholder meeting, including details on voting procedures and where related documents are available. This directly relates to the governance and scheduling of the Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R), as it provides crucial information about the meeting itself, even though it's a rescheduling announcement.
2024-04-09 English
Nombre de droits de vote au 31 mars 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF regulations) and provides a snapshot of the share capital and voting rights as of March 31, 2024. This type of mandatory periodic disclosure regarding share structure and voting rights, especially when published monthly, is a specific regulatory filing. It does not fit the definitions for Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general announcement of a report (RPA). It is a specific regulatory disclosure concerning capital structure, which aligns best with the general category for regulatory filings that don't fit elsewhere, or potentially a specific capital/financing update, but given the mandatory, periodic nature tied to share count disclosure, 'Regulatory Filings' (RNS) is the most appropriate general fit, although 'Share Issue/Capital Change' (SHA) is also relevant. However, since this is a routine monthly disclosure of existing capital structure rather than a new issuance or change, RNS serves as the best fit for mandatory, non-standard reporting.
2024-04-02 French
Number of voting rights as of March 31, 2024
Share Issue/Capital Change Classification · 1% confidence The document explicitly states it is a 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' as of March 31, 2024, referencing French commercial code (Code de Commerce) and AMF regulations. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure transparency. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a regulatory disclosure concerning share capital, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Monthly Share Capital Disclosure'. However, given the content focuses purely on the share count and voting rights, it is a specific type of regulatory update. Since 'RNS' is the general regulatory fallback and the content is a mandatory disclosure of share capital structure, RNS is the most appropriate fit among the provided options.
2024-04-02 English
Nicox - Lettre aux Actionnaires
Board/Management Information Classification · 1% confidence The document is explicitly titled as a 'Lettre aux Actionnaires' (Letter to Shareholders) from the new CEO, Gavin Spencer. It discusses the upcoming 'Assemblée générale ordinaire et extraordinaire' (Annual General Meeting and Extraordinary General Meeting) scheduled for April 10th, solicits shareholder support, and asks them to vote in favor of resolutions, specifically mentioning the need for financing renewal at this meeting. This content strongly indicates it is material prepared for or in connection with the Annual General Meeting, often included in proxy materials or as a direct communication leading up to it. Given the context of soliciting votes and discussing meeting dates, the most appropriate classification is AGM Information (AGM-R), as it is a direct communication related to the AGM.
2024-03-22 French
Nicox's Shareholder Letter
Investor Presentation Classification · 1% confidence The document is explicitly titled as a 'Shareholder Letter' from the CEO addressed to shareholders regarding an 'upcoming Extraordinary General Meeting' scheduled for April 10th. The letter discusses the company's strategy (NCX 470), financing needs, and explicitly asks shareholders to 'vote in favor of the resolutions' at the EGM. This content—a direct communication to shareholders soliciting support for necessary corporate actions (like renewing financing resolutions) at a general meeting—is characteristic of materials distributed ahead of a shareholder meeting, which falls under the scope of Proxy Solicitation & Information Statement (PSI) or potentially AGM-R if it were the Annual General Meeting. Since it is an 'Extraordinary General Meeting' (EGM) and the content is a direct appeal/information statement related to the required votes, PSI is the most appropriate classification for soliciting support for resolutions. However, given the context of a CEO letter directly tied to an upcoming general meeting where votes are required, AGM-R (which covers AGM materials, often encompassing EGM materials in broader contexts) or PSI are the closest fits. PSI specifically covers materials sent to request votes. Since the letter is a direct appeal to vote on resolutions necessary for financing, PSI is highly relevant. If the document were the actual proxy statement, PSI would be certain. As a CEO letter urging attendance and voting at an EGM, it functions as a key component of the proxy solicitation process. Given the strong emphasis on the upcoming meeting and voting, PSI is selected over AGM-R (which usually implies the formal AGM).
2024-03-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.